GleamWall
中文EN

NTHI NEONC TECHNOLOGIES HOLDINGS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1979414 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY12.0%
TTM EPS YoY25.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-642.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets241.6%
Debt / equity—
Current ratio0.38x
Interest coverage-15.69x

Cash quality & payout

Operating cash flow / net income0.48x
Accruals ratio-337.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0—$0$0$0$39,990$20,000
R&D expense$1.31M$2.65M$1.29M$1.25M$715,038$677,332$998,222$1.08M
SG&A expense$636,620$895,559$488,709$2.08M$902,985$984,262$849,485$705,737
Operating income-$5.83M-$14.07M-$7.06M-$13.70M-$6.93M-$5.71M-$31.90M-$2.11M
Interest expense$97,508$234,370$982,624$1.28M$869,815$48,750$308,922-$2,401
Net income-$4.44M-$14.24M-$8.82M-$15.52M-$8.62M-$5.68M-$32.33M-$2.25M
EPS (basic)-0.28-0.58-0.38—-0.45-0.30-1.78—
EPS (diluted)-0.28-0.58-0.38—-0.45-0.30-1.78—
Weighted avg. shares (diluted)25.78M24.66M23.29M—19.21M19.03M18.14M—
Balance sheet
Cash & equivalents$6.17M$1.97M$138,601$58,729$1.51M$125,039$5.44M$64,893
Current assets$8.46M$4.19M$2.10M$1.39M$2.96M$1.65M$7.36M$2.20M
Intangibles$474,537$481,481$488,426$500,000————
Total assets$9.30M$5.23M$3.33M$2.82M$4.08M$2.99M$8.44M$3.42M
Current liabilities$22.24M$23.51M$16.29M$20.04M$15.59M$14.48M$18.07M$8.92M
Total liabilities$22.48M$23.76M$16.56M$20.33M$15.90M$14.80M$18.07M$8.92M
Shareholders' equity-$13.17M-$18.53M-$13.23M-$17.51M-$11.81M-$11.82M-$9.62M-$5.50M
Shares outstanding28.85M25.93M24.83M21.99M19.47M19.03M19.03M18.09M
Cash flow statement
Operating cash flow-$5.09M-$4.77M-$6.99M-$3.59M-$5.81M-$5.31M-$5.65M-$954,404
Financing cash flow$9.28M$6.60M$7.07M$2.64M$7.20M$0$11.02M-$315,330
Stock-based compensation$267,565$5.65M$2.73M$9.59M$5.04M$3.53M$17.40M—

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.